Keeping Track: Personalized Medicine For Lung Cancer Evolves; Idelvion Is CBER's First Novel Approval In 2016
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Bromday Larger Bottle Gets Wink From Advisory Cmte. Still Torn On Safety
FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee said there are good reasons for FDA to approve larger fill sizes for Ista’s ocular anti-inflammatory drops, although there isn’t enough evidence to say using them in both eyes would be safe.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.